United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

9 Dec 2016
Change (% chg)

$-0.65 (-4.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

BRIEF-Stemline Therapeutics reports Q3 financial results

* Stemline Therapeutics reports third quarter 2016 financial results and highlights recent regulatory and clinical progress

BRIEF-Stemline announces seven presentations

* Stemline announces seven presentations, including oral presentation of updated SL-401 phase 2 BPDCN data, at upcoming ASH meeting Source text for Eikon: Further company coverage:

BRIEF-Stemline Therapeutics expect to provide further updates around multiple SL-401

* Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For SL-401

BRIEF-Stemline Therapeutics Q2 loss per share $0.52

* Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress

Select another date: